Region's First Early Detection Alzheimer's Centre Lunches in Abu Dhabi
The centre will offer advanced blood tests that can identify risk as early as age 40.
Apr 22, 2025
Abu Dhabi is set to open the Middle East and North Africa's first centre dedicated to the early biochemical detection of Alzheimer's disease, offering advanced blood tests that can identify risk as early as age 40. Developed by the National Reference Laboratory (NRL), part of the M42 Group, in partnership with Neurocode International, the centre is scheduled to launch within two months.
Replacing invasive diagnostic procedures, the new facility will use blood-based biomarkers to detect early signs of Alzheimer's years before symptoms appear—providing a critical window for early intervention. With no known cure and over 55 million people affected globally, early detection is expected to support preventive action, including lifestyle adjustments and targeted drug therapies that may slow disease progression.
The centre will also support diagnostics for other neurological disorders, including Parkinson's disease and myasthenia gravis, and is positioned to become one of the region's most advanced brain health laboratories. It will serve both local and international patients, with discussions underway regarding insurance coverage and final location.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mid East Info
2 days ago
- Mid East Info
KFSHRC First in the Middle East to Implant AI-Powered Brain-Sensing Device for Treating Neurological Disorders
In a landmark medical achievement, King Faisal Specialist Hospital & Research Centre KFSHRC has become the first institution in the Middle East to successfully implant an AI-powered brain-sensing device designed for the treatment of complex neurological disorders. The breakthrough ushers in a new era of real-time, adaptive neuromodulation therapy, offering renewed hope for patients suffering from Parkinson's disease, epilepsy, and other movement disorders. The device utilizes artificial intelligence to continuously monitor the brain's electrical activity, identifying abnormal neural signals and delivering precisely targeted electrical impulses to restore neurological balance. Powered by a closed-loop system, the device automatically adjusts stimulation in real time based on the patient's brain activity, enabling highly responsive, personalized therapy and consistent symptom control throughout the day. The minimally invasive procedure, typically completed within three to five hours, has shown the potential to reduce patients' reliance on medication by as much as 50%. This cuts down detrimental side effects and enhances patients' autonomy and quality of life. Initial outcomes suggest rapid post-operative recovery and tangible improvements in symptom control within weeks. This breakthrough reflects the leadership and clinical excellence of KFSHRC's Neuroscience Centre of Excellence, which provides comprehensive, multidisciplinary care for adult and paediatric neurological cases. The Center leads the region in deep brain stimulation (DBS) for movement disorders, stereotactic EEG for epilepsy, and AI-based diagnostics for cognitive conditions and autism. Through continuous innovation and a patient-centred approach, it is redefining regional standards in neuroscience and setting new benchmarks in precision brain health. It is noteworthy that KFSHRC has been ranked first in the Middle East and Africa and 15th globally in the list of the world's top 250 Academic Medical Centres for the third consecutive year and recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. Additionally, it was included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine.
Mid East Info
24-05-2025
- Mid East Info
AI Brain Implant at KFSHRC Offers Parkinson's Relief with 50% Less Medication Riyadh hospital pioneers AI-powered therapy that delivers real-time brain stimulation for chronic neurological disorders
Riyadh King Faisal Specialist Hospital & Research Centre (KFSHRC) in Riyadh has successfully executed a groundbreaking procedure in the Middle East, implanting an advanced smart device within the brain to help manage chronic neurological disorders. This device monitors abnormal electrical activity and sends targeted electrical impulses to the affected regions, aiming to alleviate symptoms, decrease dependence on medication, and enhance patients' quality of life, independence, and health stability. This state-of-the-art innovation enables patients to better control neurological symptoms and potentially lower medication doses by as much as 50%, reducing side effects and improving daily activities- especially for those with Parkinson's disease, epilepsy, and movement disorders. The device's built-in artificial intelligence rapidly analyses brain signals to detect abnormal activity patterns and responds by providing targeted electrical stimulation to restore neural balance. This allows for highly accurate, adaptive treatment that adjusts to the patient's condition in real time without requiring continuous manual intervention from healthcare professionals. While benefits start to appear within the first few weeks post-implantation, achieving optimal results requires a fine-tuning period of one to three months, during which electrical responses are calibrated according to real-time brain signals collected by the device. The procedure utilises minimally invasive methods lasting only three to five hours, avoiding large surgical cuts. This approach lessens recovery time, minimises complications, and encourages a quicker return to everyday activities. This achievement highlights KFSHRC's ongoing progress in harnessing artificial intelligence and medical innovation to provide high-precision, specialised care, meet patient needs, and shape an advanced therapeutic model for the region and beyond. It is noteworthy that KFSHRC has been ranked first in the Middle East and North Africa and 15th globally in the list of the world's top 250 Academic Medical Centres for the third consecutive year and recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. Additionally, it was included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine.
Egypt Independent
18-05-2025
- Egypt Independent
FDA greenlights first blood test to help diagnose Alzheimer's disease in the US
The US Food and Drug Administration has given marketing clearance to a blood test to help diagnose Alzheimer's disease, making the test the first to get signoff to aid in the early detection of the disease in the United States. The test, called the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, is for adults 55 and older who are showing signs and symptoms of Alzheimer's disease, the FDA announced Friday. It works by measuring two proteins in blood plasma: pTau217 and beta-amyloid 1-42. A ratio of those proteins tends to correlate with the occurrence or absence of amyloid plaques in the brain, which are among the hallmarks of Alzheimer's disease. The test does not measure amyloid directly but can signal its presence. However, there remains no current single test to diagnose Alzheimer's disease. Doctors primarily rely on a variety of tools to diagnose the condition, which may include medical history, neurological exams, cognitive and functional evaluations, brain imaging, spinal fluid analysis and, more recently, blood tests. The FDA said the results of the newly cleared blood test must be assessed in conjunction with other clinical information from a patient. 'Alzheimer's disease impacts too many people, more than breast cancer and prostate cancer combined,' FDA Commissioner Dr. Martin Makary said in Friday's announcement. 'Knowing that 10% of people aged 65 and older have Alzheimer's, and that by 2050 that number is expected to double, I am hopeful that new medical products such as this one will help patients.' According to the FDA, the new blood test – developed by the Pennsylvania-based biotechnology company Fujirebio Diagnostics Inc. – can help increase access to Alzheimer's disease detection and reduce reliance on positron emission tomography or PET scans, a type of imaging that can reveal amyloid plaques in the brain but can be expensive, costing thousands of dollars without insurance. The FDA said it reviewed clinical trial data on the new blood test, involving plasma samples collected from 499 adults who were cognitively impaired. The samples were evaluated using the blood test, and the results were compared with the results from patients' PET scans or separate testing using cerebrospinal fluid samples, such as from spinal taps. The data showed that 91.7% of adults with positive results using the blood test had the presence of amyloid plaques confirmed by their PET scan or cerebrospinal fluid test, and 97.3% of people with negative results had a negative amyloid PET scan or cerebrospinal fluid test result, according to the FDA. The agency added that the risks associated with the blood test are mainly the risk of a false positive or false negative test result. A 'new era' of Alzheimer's research Preventive neurologist Dr. Richard Isaacson, who established one of the first Alzheimer's prevention clinics in the United States, said he has been using this blood test for years for research and applauded the FDA clearance. 'It can provide better clarity into whether a person experiencing memory loss may have Alzheimer's disease. They can take this test as a screening test,' said Isaacson, director of research at the Institute for Neurodegenerative Diseases in Florida. Compared with costly PET scans or spinal taps, 'this is a much more simple screening test, with reasonable accuracy, to tell the physician that a person with cognitive decline has symptoms that are actually due to Alzheimer's disease.' But Isaacson warned that while the FDA clearance is 'an important step forward' for the field, more research is needed to help inform how blood test results should be interpreted and used to make clinical decisions. 'I think the next step as a field is, we need to advance education about what these tests mean and what they don't and who they should be used for,' he said. 'Because they mean different things in different people depending on their risk factors and whether or not they have symptoms. So we're still early.' Fujirebio Diagnostics designed the blood test to help detect Alzheimer's disease early, when interventions are more effective, president and CEO Monte Wiltse said in a news release last year , when the company filed its test with the FDA. 'An early and accurate diagnosis will also facilitate the development of new drug therapies, which are urgently needed as the prevalence of AD increases with a rapidly aging population globally,' Wiltse said. It's estimated that more than 2 in 5 people over the age of 55 in the United States – about 42% – will develop dementia in their later years. But in some cases, deposits of amyloid can start to accumulate in the brain decades before Alzheimer's symptoms begin. Early detection of these amyloid plaques could open the door for a person to take steps to slow the progression of disease, such as starting preventive treatment with medications. 'For too long Americans have struggled to get a simple and accurate diagnosis, with today's action by the FDA we are hopeful it will be easier for more individuals to receive an accurate diagnosis earlier,' Dr. Maria Carrillo, chief science officer and medical affairs lead at the Alzheimer's Association, said in a statement Friday. There are a variety of laboratory-developed tests on the market that can be used to detect blood-based biomarkers associated with Alzheimer's, according to the Alzheimer's Association, as well as experimental tests. But the Fujirebio Diagnostics test is the first one cleared by the FDA. 'Blood-based biomarkers are reshaping how we identify and understand Alzheimer's disease,' Carrillo said. 'At the same time, there are important questions for health care professionals to consider; in particular, who should be tested and when.' For now, the FDA's clearance 'marks a major milestone,' said Dr. Howard Fillit, co-founder and chief science officer at the Alzheimer's Drug Discovery Foundation. 'The ability to diagnose Alzheimer's earlier with a simple blood test, like we do for cholesterol, is a game changer, allowing more patients to receive treatment options that have the potential to significantly slow or even prevent the disease,' Fillit said in an email Friday. 'This is a clear example of the new era of Alzheimer's research where innovation, science and technology come together to develop more accessible, affordable and scalable tools that will pave the way for additional regulatory approvals of diagnostic tools.'
